New cocktail of drugs shows promise for Tough-to-Treat throat cancer
NCT ID NCT06059261
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding an immunotherapy drug (envafolimab) and a blood-vessel blocker (endostatin) to standard chemoradiotherapy can improve outcomes for 30 people with locally advanced nasopharyngeal carcinoma. The main goal is to see how many patients have a complete disappearance of their tumors after the initial treatment phase. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- envafolimab (an immunotherapy drug) combined with chemotherapy (cisplatin, gemcitabine) and recombinant human endostatin (a drug that blocks blood vessel growth to tumors)
- What this could lead to
- If successful, this combination could offer a more effective treatment option for people with advanced nasopharyngeal cancer, potentially improving tumor shrinkage and delaying progression.
- What could go wrong
- This is a small, early-phase (phase II) study with only 30 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and it is not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers